Pulse Biosciences Files Amended 10-K: Key Governance, Compensation, and Strategic Updates for Investors

Summary of the Amendment

Pulse Biosciences, Inc. (Nasdaq: PLSE) has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment provides previously omitted disclosures required by Items 10-14 of Part III of Form 10-K, including information on directors, executive officers, corporate governance, executive compensation, security ownership, and related party transactions. The amendment also includes updated certifications under Section 302 of the Sarbanes-Oxley Act, reflecting changes since the original filing.

Key Points for Investors

• Corporate Governance Structure: Pulse Biosciences maintains an Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Strategic Advisory Committee. Each operates under a Board-approved charter and is integral to the company’s governance and oversight.
  Potential Impact: Strong governance can reassure investors about risk oversight and regulatory compliance.
• Committee Composition and Meetings: The committees are composed of independent directors. The company provides a detailed breakdown of committee memberships and the number of meetings held in 2025, underscoring a focus on transparency and governance best practices.
• Corporate Governance Guidelines: All directors are expected to attend the annual shareholders meeting, with full compliance in 2025. The company is also subject to Nasdaq and California diversity regulations for its Board.
• Insider Trading Policy Update: In Q1 2026, the company amended its insider trading policy. All members of “Senior Leadership” must now obtain Audit Committee approval to adopt any Rule 10b5-1 trading plans, and the quarterly open trading window has been lengthened. The revised policy is filed as Exhibit 19.1.
  Potential Impact: Enhanced oversight could reduce the risk of improper trading, supporting investor confidence.
• Communication with the Board: Pulse Biosciences has a formal process for shareholder communications to the Board, which is reviewed periodically to ensure effectiveness.
• Compensation Committee: Comprised of Manmeet S. Soni (Chair), Robert W. Duggan, and Richard A. van den Broek. All are independent directors.
• Executive Compensation: In a significant move, the Compensation Committee determined in February 2026 that the company’s 2025 corporate objectives had not been achieved, and therefore awarded no cash bonuses for 2025 to executive officers.
  Potential Impact: This decision signals accountability and may influence investor sentiment regarding leadership alignment with shareholder interests.
• Outstanding Equity Awards: The report provides detailed tables of equity awards held by Named Executive Officers (NEOs) as of December 31, 2025. Notably, the company had no outstanding stock awards other than options as of year-end.
• Notable Executive Agreements:
  • Paul A. LaViolette (Chief Executive Officer): His employment agreement includes significant performance-based option incentives. For example, one-third of 30% of his options (150,000 shares) vest only if the company achieves a market capitalization of at least \$3.0 billion for 270 consecutive days and \$48 million in product revenue over 12 months. Further tranches vest at higher capitalization and revenue thresholds (\$4B/\$115M, \$5B/\$175M).
  • Other NEOs: Similar performance-restricted option packages are granted, incentivizing long-term value creation.

  Potential Impact: These aggressive performance hurdles tie leadership compensation directly to substantial shareholder value creation, potentially aligning executive and investor incentives.

• 2025 Equity Grants Subject to Shareholder Approval: Certain option grants for directors and executives are contingent upon future shareholder approval of additional shares under the Equity Incentive Plan.
  Potential Impact: If not approved, executives may not receive these incentives, which could affect retention or recruitment.
• Director Compensation Flexibility: Non-employee directors may elect to convert all or part of their cash retainer into stock options, using a formula that multiplies the cash amount by three and divides by the fair market value at the time of grant.
• Company Status: Pulse Biosciences is a non-accelerated filer, a smaller reporting company, and is not an emerging growth company or a shell company. It is current with all required SEC filings.
• Market Capitalization and Share Count: As of March 31, 2026, public float stood at approximately \$394.3 million, with 68,225,067 shares outstanding.
• Forward-Looking Statements Warning: The amendment contains forward-looking statements subject to significant risks and uncertainties. Investors are cautioned not to place undue reliance on such statements.

Potentially Price-Sensitive Information

• No 2025 Executive Bonuses Paid: The Compensation Committee’s decision not to pay cash bonuses reflects underperformance on stated objectives and could impact investor perception of management effectiveness and alignment with shareholders.
• Material Performance Hurdles for CEO and NEO Compensation: The aggressive vesting conditions for executive stock options mean actual realized compensation will depend heavily on market cap and revenue growth—offering investors transparency and leverage over management rewards.
• Amended Insider Trading Policy: Recent changes add controls and transparency, a move likely to be viewed positively by institutional investors.
• Equity Awards Subject to Shareholder Vote: Certain director and executive options require future shareholder approval to become effective, potentially affecting long-term retention of key leaders.

Conclusion

This amended 10-K filing provides critical updates for shareholders regarding the governance structure, executive and director compensation (including a lack of 2025 bonuses), performance-based incentive alignment, and a strengthened insider trading policy. These disclosures—especially the non-payment of bonuses, the ambitious performance criteria for stock option vesting, and the requirement for shareholder approval of new equity grants—may influence share price direction based on investor perception of leadership accountability, governance quality, and future growth prospects.

Disclaimer: This article is a summary and interpretation of Pulse Biosciences, Inc.’s amended 10-K/A filing as of April 30, 2026. It does not constitute investment advice. Investors should consult the full SEC filing and their financial advisors before making investment decisions.

View PULSE BIOSCIENCES, INC. Historical chart here